双示踪剂PET/CT方案联合[18F]-FDG与[68Ga]Ga-FAPI-46用于肿瘤成像:一项概念验证研究
研究纳入接受[18F]-FDG PET/CT及随后追加[68Ga]Ga-FAPI-46的双示踪剂PET/CT的患者,由两名读片者视觉比较单示踪剂与双示踪剂PET/CT的检出率并分析肿瘤及转移灶的靶本比。双示踪剂PET/CT检出率在4例患者中与单示踪剂相当、在2例患者中更优,靶本比在双示踪剂PET/CT中显著更高。结论认为单次会话内双示踪剂[18F]-FDG/[68Ga]Ga-FAPI-46 PET/CT可行且有潜力,可能较单用[18F]-FDG PET/CT灵敏度更优且不损害各自扫描的独立评估。
要点
- 双示踪剂PET/CT检出率在4例患者中与单示踪剂相当,在2例患者中更优。
- 双示踪剂PET/CT的靶本比显著高于单示踪剂PET/CT。
- 单次会话内双示踪剂[18F]-FDG/[68Ga]Ga-FAPI-46 PET/CT可行且有潜力。
核心结论
- 单次会话内双示踪剂[18F]-FDG/[68Ga]Ga-FAPI-46 PET/CT可行且有潜力。
- 双示踪剂方法可能较单用[18F]-FDG PET/CT灵敏度更优,且不损害各自扫描的独立评估。
研究设计与样本
- 所有患者接受[18F]-FDG PET/CT,并在[18F]-FDG PET/CT后追加注射[68Ga]Ga-FAPI-46行双示踪剂PET/CT。
- 两名读片者视觉比较单示踪剂与双示踪剂PET/CT的检出率,并分析肿瘤及转移组织的靶本比。
主要发现
- 双示踪剂PET/CT检出率在4例患者中视觉上与单示踪剂PET/CT相当,在2例患者中更优。
- 双示踪剂PET/CT的靶本比显著高于单示踪剂PET/CT。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Imaging studies with PET tracers acting as fibroblast activation protein inhibitors (FAPIs) show promising results that could usefully complement [18F]-FDG in cancer imaging. Methods: All patients received [18F]-FDG PET/CT and dual-tracer PET/CT after an additional injection of [68Ga]Ga-FAPI-46 after the [18F]-FDG PET/CT. Two readers visually compared detection rate and analyzed target-to-background ratios for tumor and metastatic tissue in single- and dual-tracer PET/CT. Results: Detection rate in dual-tracer PET/CT was visually as good as that in single-tracer PET/CT in 4 patients and superior in 2 patients, whereas target-to-background ratios were significantly higher in dual-tracer PET/CT. Conclusion: Dual-tracer [18F]-FDG/[68Ga]Ga-FAPI-46 PET/CT within a single session is feasible and has potential. The dual-tracer approach may have superior sensitivity to [18F]-FDG PET/CT alone without compromising individual assessment of either scan.
引用
- Roth KS, Voltin CA, van Heek L, et al. Dual-Tracer PET/CT Protocol with [18F]-FDG and [68Ga]Ga-FAPI-46 for Cancer Imaging: A Proof of Concept. J Nucl Med. 2022. PMID: 35422446. doi:10.2967/jnumed.122.263835
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。